Key Takeaways
- • SpaceX prices a $75 billion initial public offering at its designated price range, marking a major liquidity event in the commercial space sector.
- • Apollo Global Management leads a capital commitment for a Broadcom-led initiative to construct artificial intelligence infrastructure serving companies including Anthropic, signaling institutional investment in AI compute capacity.
- • GSK (GlaxoSmithKline) acquires Nuvalent, a cancer therapy specialist, expanding its oncology portfolio through strategic M&A activity.
- • Gibson Dunn, Davis Polk, and Sullivan & Cromwell are positioned as key legal advisors across these major transactions, reflecting their prominence in capital markets and healthcare M&A work.
Summary
Three major transactions dominated capital markets activity in the week of June 12, 2026, spanning aerospace, artificial intelligence infrastructure, and pharmaceutical acquisitions. SpaceX's $75 billion initial public offering, priced at its designated range, represents a significant milestone for the commercial space industry and marks a substantial liquidity event for existing shareholders. The IPO reflects ongoing institutional appetite for space technology and commercial launch services.
Parallel to SpaceX's public offering, Apollo Global Management announced a capital commitment to support a Broadcom-led initiative aimed at building artificial intelligence infrastructure. The project is designed to serve multiple enterprise customers, including Anthropic, indicating growing institutional investment in the foundational compute capacity required for large-language model development and deployment. This commitment underscores the strategic importance of AI infrastructure as a bottleneck asset class and the willingness of alternative asset managers to deploy capital into physical infrastructure supporting the artificial intelligence ecosystem.
In the pharmaceutical sector, GSK completed the acquisition of Nuvalent, a cancer therapy specialist, signaling continued consolidation within oncology and targeted therapeutics. This transaction reflects the pharmaceutical industry's ongoing strategy to expand pipeline depth and acquire specialized expertise in high-value therapeutic areas.
Top-tier law firms Gibson Dunn, Davis Polk, and Sullivan & Cromwell served as principal legal advisors across these transactions, underscoring their dominance in capital markets advisory, healthcare M&A, and complex cross-border deal structuring.
Parallel to SpaceX's public offering, Apollo Global Management announced a capital commitment to support a Broadcom-led initiative aimed at building artificial intelligence infrastructure. The project is designed to serve multiple enterprise customers, including Anthropic, indicating growing institutional investment in the foundational compute capacity required for large-language model development and deployment. This commitment underscores the strategic importance of AI infrastructure as a bottleneck asset class and the willingness of alternative asset managers to deploy capital into physical infrastructure supporting the artificial intelligence ecosystem.
In the pharmaceutical sector, GSK completed the acquisition of Nuvalent, a cancer therapy specialist, signaling continued consolidation within oncology and targeted therapeutics. This transaction reflects the pharmaceutical industry's ongoing strategy to expand pipeline depth and acquire specialized expertise in high-value therapeutic areas.
Top-tier law firms Gibson Dunn, Davis Polk, and Sullivan & Cromwell served as principal legal advisors across these transactions, underscoring their dominance in capital markets advisory, healthcare M&A, and complex cross-border deal structuring.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.